VISEN Pharmaceuticals Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Other Revenue	0.84	2.78	-1.67	-2.3
Revenue	0.84	2.78	-1.67	-2.3
Gross Profit	0.84	2.78	-1.67	-2.3
Selling, General & Admin	102.84	86.43	79.94	177.45
Research & Development	98.23	90.52	57.69	179.55
Operating Expenses	201.06	176.96	137.63	357
Operating Income	-200.22	-174.18	-139.3	-359.29
Interest Expense	-0.11	-0.16	-0.32	-0.62
Interest & Investment Income	7.75	6.77	11.15	5.57
Currency Exchange Gain (Loss)	-6.47	2.69	4.71	79.78
Other Non Operating Income (Expenses)	-17.74	-17.37	-16.28	-14.3
EBT Excluding Unusual Items	-216.79	-182.24	-140.05	-288.86
Gain (Loss) on Sale of Assets	-	-	-0.24	-0.1
Other Unusual Items	-	-	-109.28	-
Pretax Income	-216.79	-182.24	-249.57	-288.97
Net Income	-216.79	-182.24	-249.57	-288.97
Net Income to Common	-216.79	-182.24	-249.57	-288.97
Shares Outstanding (Basic)	97	94	94	-
Shares Outstanding (Diluted)	97	94	94	-
EPS (Basic)	-2.24	-1.95	-2.67	-
EPS (Diluted)	-2.24	-1.95	-2.67	-
Free Cash Flow	-180.36	-140.98	-271.83	-248.03
Free Cash Flow Per Share	-1.86	-1.51	-2.90	-
Gross Margin	100.00%	100.00%	-	-
Operating Margin	-23807.37%	-6272.16%	-	-
Profit Margin	-25777.76%	-6562.55%	-	-
Free Cash Flow Margin	-21445.66%	-5076.52%	-	-
EBITDA	-200.21	-173.46	-137.79	-357.55
D&A For EBITDA	0.01	0.72	1.51	1.74
EBIT	-200.22	-174.18	-139.3	-359.29

Source: S&P Global Market Intelligence. Standard template. Financial Sources.